tiprankstipranks
Advertisement
Advertisement

GALT Stock Latest News

Galectin Therapeutics files $200M mixed securities shelf
The FlyGalectin Therapeutics files $200M mixed securities shelf
1M ago
GALT
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
1M ago
GALT
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
PremiumCompany Announcements
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
2M ago
8K
GALT
Galectin Therapeutics appoints Henry Brem to board of directors
PremiumThe Fly
Galectin Therapeutics appoints Henry Brem to board of directors
2M ago
GALT
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
PremiumRatings
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
2M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
PremiumCompany AnnouncementsGalectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
2M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Premium
Company Announcements
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
3M ago
GALT
Galectin Therapeutics Approves Retention Bonuses for Key Executives
Premium
Company Announcements
Galectin Therapeutics Approves Retention Bonuses for Key Executives
4M ago
8K
GALT
Galectin Therapeutics announces board resignation of Marc Rubin
PremiumCompany Announcements
Galectin Therapeutics announces board resignation of Marc Rubin
4M ago
8K
GALT
Galectin Advances Belapectin Program, Secures New Insider Financing
PremiumCompany Announcements
Galectin Advances Belapectin Program, Secures New Insider Financing
5M ago
8K
GALT
Galectin Therapeutics provides regulatory update following FDA written response
PremiumThe Fly
Galectin Therapeutics provides regulatory update following FDA written response
5M ago
GALT
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
PremiumThe Fly
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
5M ago
GALT
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
PremiumCompany AnnouncementsGalectin Therapeutics Holds 2025 Annual Stockholders Meeting
5M ago
8K
GALT
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Premium
Company Announcements
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
5M ago
8K
GALT
Galectin Therapeutics Reports Q3 2025 Financials
Premium
Company Announcements
Galectin Therapeutics Reports Q3 2025 Financials
6M ago
GALT
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
PremiumRatings
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
6M ago
GALT
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
PremiumThe Fly
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
6M ago
GALT
Galectin Therapeutics presents NAVIGATE trial results at AASLD
PremiumThe Fly
Galectin Therapeutics presents NAVIGATE trial results at AASLD
6M ago
GALT
Galectin Therapeutics Presents Promising NAVIGATE Trial Results
PremiumCompany Announcements
Galectin Therapeutics Presents Promising NAVIGATE Trial Results
6M ago
8K
GALT
Galectin Therapeutics Highlights Promising Belapectin Results
PremiumCompany AnnouncementsGalectin Therapeutics Highlights Promising Belapectin Results
8M ago
8K
GALT
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
9M ago
ING
AMPY
Galectin Therapeutics Reports Reduced Losses in Q2 2025
Premium
Company Announcements
Galectin Therapeutics Reports Reduced Losses in Q2 2025
9M ago
GALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >